Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012
Cited by 609 works. doi:10.1016/s1470-2045(12)70063-3
Authors
- Luis G Paz-Ares
- Filippo de Marinis
- Mircea Dediu
- Michael Thomas
- Jean-Louis Pujol
- Paolo Bidoli
- Olivier Molinier
- Tarini Prasad Sahoo
- Eckart Laack
- Martin Reck
- Jesus Corral
- Symantha A. Melemed
- William J. John
- Nadia Chouaki
- Annamaria Hayden Zimmermann
- Carla Visseren‐Grul
- Cesare Gridelli
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- AJCC Cancer Staging Manual
- Analysis of Binary Data
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- EuroQol - a new facility for the measurement of health-related quality of life
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy